A Phase 1 Study of Ziftomenib Combinations in People With Acute Myeloid Leukemia

Full Title

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Purpose

Researchers want to find the best doses of ziftomenib to use with other drugs to treat leukemia. The people in this study have acute myeloid leukemia (AML) that keeps growing even with treatment. In addition, they have AML with changes in the NPM1, KMT2A, or FLT3 genes.

A protein called menin can promote the growth and survival of cancer cells. Ziftomenib blocks the menin pathway, which may help slow or stop AML growth. Ziftomenib is taken orally (by mouth).

If you join this study, you will take ziftomenib plus one of these other leukemia treatments:

• FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin)
• LDAC (low-dose cytarabine)
• Gilteritinib

Contact

For more information and to see if you can join this study, please call Dr. Aaron Goldberg’s office at 646-608-3752.